Dr Joachim Feldwisch | Director of Preclinical Development
Affibody Ab

Dr Joachim Feldwisch, Director of Preclinical Development, Affibody Ab

Dr. Feldwisch, Director Preclinical Development of Affibody AB, joined the company in 2002. He has more than 20 years of experience in life science research with particular expertise in protein engineering of alternative scaffolds, protein biochemistry and development of drug candidates for clinical trials. He received his MSc in Biology with main focus on biochemistry and molecular biology from the University of Cologne and earned his PhD at the Max-Planck-Institute für Züchtungsforschung in Cologne in 1992. In the following years he worked at Pharmacia, Pharmacia&Upjohn and later Biovitrum both with biotherapeutics and small molecule pharmaceuticals. His current research interests include optimization of small scaffold proteins as well as preclinical and clinical development of Affibody molecules for therapeutic use.


EAC 2017 Day 2, Wednesday 1st November 2017 @ 11:25

Engineering an Affibody® fusion protein trap towards therapeutic blocking of IL-17 in man

  • Psoriasis is an IL-17 driven disease.
  • An Affibody® based 18.6 kDa ligand trap was engineered to block IL-17A with femtomolar affinity
  • The trivalent bispecific fusion protein blocks IL-17 with unparalleled affinity and displays long plasma half-life as shown in man
  • Early development and data from Phase I/II will be presented

back to speakers